Drug data last refreshed 2d ago
RITALIN (methylphenidate hydrochloride) is an oral CNS stimulant approved in 1955 for ADHD and other conditions. It works by blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their availability in the extraneuronal space. The drug is indicated for ADHD as a primary use, with off-label applications in fatigue, anxiety disorders, and panic disorder.
With LOE approaching and modest Part D spending of $756K across ~5,900 claims (2023), this legacy product faces declining revenue trajectory and smaller brand team resource allocation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Worked on RITALIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moRITALIN presents limited career growth opportunities given its LOE-approaching status, minimal Part D spending, and lack of linked job openings. Work on this product is typically restricted to legacy brand maintenance, compliance, and specialty market development rather than strategic growth initiatives.